TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26897923

Group type: EXPERIMENTAL
Intervention: 0.40 USD for each of four visits
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no cash)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: More antenatal visits
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.20 USD for each of four visits
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.40 USD for a single first trimester visit only
Number of subjects: 23
Study: 23340983

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA) at 20-22 °C (GA I)
Number of subjects: 90

Group type: COMPARATOR
Intervention: General Anesthesia (GA) at 23-25 °C (GA II)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Epidural Anesthesia (EA) at 20-22 °C (EA I)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Epidural Anesthesia (EA) at 23-25 °C (EA II)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Femoral-Sciatic Block (FS) at 20-22 °C (FS I)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Femoral-Sciatic Block (FS) at 23-25 °C (FS II)
Number of subjects: 90
Study: 21975350

Group type: EXPERIMENTAL
Intervention: Oral letrozole (2.5 mg/day)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Oral exemestane (25 mg/day)
Number of subjects: 250
Study: 18304286

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg taken on demand for up to 12 weeks
Number of subjects: 188
Study: 17000812

Group type: EXPERIMENTAL
Intervention: Standard combined spinal epidural (Std CSE) with hyperbaric bupivacaine 10 mg and intrathecal fentanyl 15 microg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sequential combined spinal epidural (Seq CSE) with hyperbaric bupivacaine 5 mg and intrathecal fentanyl 15 microg
Number of subjects: 40
Study: 14580657

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study: 10962915

Group type: EXPERIMENTAL
Intervention: DMARD + prednisolone
Number of subjects: 26

Group type: COMPARATOR
Intervention: DMARD alone
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 26
Study: 8981127

Group type: EXPERIMENTAL
Intervention: Bovine oviductal epithelial cell co-culture
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Assisted hatching by zona drilling
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Assisted hatching by zona drilling in patients aged > or = 35 years
Number of subjects: 219
Study: 1451523

Group type: EXPERIMENTAL
Intervention: Brand new condom lot
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Condom lot aged 81 months
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Statistical predictor models using ultimate elongation, Condom Quality Index, and percent of condoms failing the airburst volume test
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Age of the condom lot
Number of subjects: 262
Study: 6691877

Group type: EXPERIMENTAL
Intervention: Midazolam-fentanyl-nitrous oxide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Thiopentone-fentanyl-nitrous oxide
Number of subjects: 100
Study: 30698339

Group type: EXPERIMENTAL
Intervention: Enhanced Support Group (ESG)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Standard Support Group (SSG)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 71
Study: 29127848

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800mg QD
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 400mg QD
Number of subjects: 1447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800mg QD and 1200mg QD
Number of subjects: 1447
Study: 25670917

Group type: EXPERIMENTAL
Intervention: Remifentanil (2 μg.kg(‐1) bolus, 2‐7 μg.kg(‐1).min(‐1) infusion)
Number of subjects: 62

Group type: COMPARATOR
Intervention: High-dose sufentanil-sevoflurane (control group)
Number of subjects: 62
Study: 25119853

Group type: EXPERIMENTAL
Intervention: Dietary cholesterol supplementation (9 g kg(‐1)) with rapeseed meal (RSM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary cholesterol supplementation (9 g kg(‐1)) with cottonseed meal (CSM)
Number of subjects: 0
Study: 22879096

Group type: EXPERIMENTAL
Intervention: Priority level 1 intervention group (immediate call of an ambulance)
Number of subjects: 942

Group type: COMPARATOR
Intervention: Standard priority level 2 control group (within 30 minutes)
Number of subjects: 942
Study: 19262229

Group type: EXPERIMENTAL
Intervention: Nicorandil (15 mg/day)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (30 mg/day)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 17852947

Group type: EXPERIMENTAL
Intervention: Once-daily administration of amphotericin B deoxycholate (1 mg/kg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Alternate-day administration of amphotericin B deoxycholate (2 mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both groups (OD and AD)
Number of subjects: 28
Study: 15377681

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Number of subjects: 10
Study: 11576953

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 1715

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 1715

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1715

Group type: EXPERIMENTAL
Intervention: Irbesartan or Amlodipine
Number of subjects: 1715
Study: 9522109

Group type: EXPERIMENTAL
Intervention: Nabumetone 2000 mg daily
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 8829021

Group type: EXPERIMENTAL
Intervention: Dorzolamide 2% TID + Timolol 0.5% BID
Number of subjects: 97

Group type: COMPARATOR
Intervention: Betaxolol 0.5% BID
Number of subjects: 97

Group type: COMPARATOR
Intervention: Timolol 0.5% BID
Number of subjects: 97
Study: 2390432

Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg three times daily and cholestyramine 4 g three times daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cholestyramine alone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Acipimox added to cholestyramine therapy
Number of subjects: 28
Study: 7409937

Group type: EXPERIMENTAL
Intervention: 5 mg of diazepam
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 60 mg of pentobarbital
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: pentobarbital
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 75
Study: 30650260

Group type: EXPERIMENTAL
Intervention: ELX-02 (0.3 mg/kg to 7.5 mg/kg)
Number of subjects: 0
Study: 27254291

Group type: EXPERIMENTAL
Intervention: Advanced cookstove intervention
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Photovoice methodology
Number of subjects: 4
Study: 23592830

Group type: EXPERIMENTAL
Intervention: EFV (600 mg) on-RIF
Number of subjects: 780

Group type: COMPARATOR
Intervention: EFV (600 mg) off-RIF
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Weight ≥60 kg on-RIF
Number of subjects: 780
Study: 21991729

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg/kg bolus followed by 0.4 microg/kg/hr infusion)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 40
Study: 18940191

Group type: EXPERIMENTAL
Intervention: Serum omega-3 fatty acids (ALA, EPA, DHA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Serum omega-3/omega-6 ratio
Number of subjects: 60
Study: 17078771

Group type: EXPERIMENTAL
Intervention: Fasting therapy (FT) consisting of 10 days of starvation followed by 5 days of refeeding
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control therapy (basic treatment consisting of pharmacotherapy and brief psychotherapy)
Number of subjects: 58
Study: 15641874

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 113
Study: 11231867

Group type: EXPERIMENTAL
Intervention: Echinaforce (Echinacea purpurea) for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 50
Study: 9080920

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 2382

Group type: EXPERIMENTAL
Intervention: Sodium reduction intervention
Number of subjects: 2382

Group type: EXPERIMENTAL
Intervention: Combined weight loss and sodium reduction intervention
Number of subjects: 2382

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2382
Study: 8403071

Group type: EXPERIMENTAL
Intervention: Nuelin liquid (NSRT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3949238

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Taurine
Number of subjects: 9

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 9
Study: 31906748

Group type: EXPERIMENTAL
Intervention: Music therapy (MT) - a single individualized session along with a recorder and journal for home use
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Music Plus - weekly group MT sessions along with a recorder and journal for home use
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control - standard of care
Number of subjects: 173
Study: 30919549

Group type: EXPERIMENTAL
Intervention: Biomarker-guided treatment strategy
Number of subjects: 894

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 894
Study: 28654556

Group type: EXPERIMENTAL
Intervention: Sufentanil 100 μg + dexmedetomidine 200 μg + normal saline 100 mL (group D)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Sufentanil 100 μg + normal saline 100 mL (group C)
Number of subjects: 210
Study: 26910198

Group type: EXPERIMENTAL
Intervention: Targeted conditions
Number of subjects: 3387

Group type: EXPERIMENTAL
Intervention: Nontargeted conditions
Number of subjects: 3387

Group type: EXPERIMENTAL
Intervention: Observation units for targeted conditions
Number of subjects: 3387

Group type: EXPERIMENTAL
Intervention: Observation units for nontargeted conditions
Number of subjects: 3387

Group type: COMPARATOR
Intervention: Changes in observation-unit stays
Number of subjects: 3387
Study: 25526455

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for older patients with stage II disease
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for older patients with stage III disease
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for older patients with colon cancer
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for older patients with rectal cancer
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Preoperative short-course radiotherapy for older patients with stage III rectal cancer
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Preoperative short-course radiotherapy for older patients with rectal cancer
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Surgery for older patients with colorectal cancer
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Surgery for rectal cancer patients aged ≥80 years
Number of subjects: 1021
Study: 21972424

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg daily for three months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for three months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg daily for three months (after atorvastatin)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metformin 1500 mg daily for three months (after placebo)
Number of subjects: 40
Study: 20816118

Group type: EXPERIMENTAL
Intervention: Fenofibrate/pravastatin combination therapy
Number of subjects: 248
Study: 18947338

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 115

Group type: COMPARATOR
Intervention: Non-penetrating sham acupuncture
Number of subjects: 115
Study: 15939064

Group type: EXPERIMENTAL
Intervention: Folic acid (2.5 mg), Vitamin B6 (25 mg), Vitamin B12 (0.5 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11826230

Group type: EXPERIMENTAL
Intervention: Ibuprofen suspension
Number of subjects: 1879

Group type: COMPARATOR
Intervention: Acetaminophen suspension
Number of subjects: 1879
Study: 10411767

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with fentanyl 1 microg.kg‐1
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% with fentanyl 1 microg.kg‐1
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% without fentanyl
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% without fentanyl
Number of subjects: 56
Study: 8775609

Group type: EXPERIMENTAL
Intervention: Dobutamine (5 micrograms/kg/min for 24 hours)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (dopamine or amrinone as indicated)
Number of subjects: 80
Study: 1955196

Group type: EXPERIMENTAL
Intervention: Troleandomycin (1 g bid over a 10‐day period)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Josamycin (same doses as T)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 6762946

Group type: EXPERIMENTAL
Intervention: Culdoscopy
Number of subjects: 395

Group type: COMPARATOR
Intervention: Minilaparotomy
Number of subjects: 395
Study: 30786753

Group type: EXPERIMENTAL
Intervention: Insuring Good Health Intervention (website and video series)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Lagged-control group
Number of subjects: 243
Study: 29118254

Group type: EXPERIMENTAL
Intervention: Novel toothbrush design
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control reference toothbrush
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both brushes
Number of subjects: 38
Study: 25424602

Group type: EXPERIMENTAL
Intervention: Rapeseed oil (RO) diet (14-27 g/day) for 13 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sunflower oil (SO) diet (14-27 g/day) for 13 weeks
Number of subjects: 21
Study: 23172400

Group type: EXPERIMENTAL
Intervention: Patient-oriented (Pa‐O) approach
Number of subjects: 220

Group type: COMPARATOR
Intervention: Prescription-oriented (Pr‐O) approach
Number of subjects: 220
Study: 21483169

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 823
Study: 19438913

Group type: EXPERIMENTAL
Intervention: Acetazolamide (Az)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 14
Study: 17530483

Group type: EXPERIMENTAL
Intervention: Thalidomide alone (200 mg/day up to 800 mg/day)
Number of subjects: 28
Study: 15005733

Group type: COMPARATOR
Intervention: Sublingual immunotherapy (SLIT) only (n=16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sublingual immunotherapy (SLIT) + one dose of BCG immunization (n=16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (inhaled therapy only, PPD-negative asthmatics allergic to HDM, n=5)
Number of subjects: 32
Study: 11487597

Group type: EXPERIMENTAL
Intervention: CHAMPS II program
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 173
Study: 9722121

Group type: EXPERIMENTAL
Intervention: Single-dose piperacillin (4 g)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Multi-dose piperacillin (3 doses of 2 g)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Combination of cephradine and metronidazole (3 doses)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Single-dose piperacillin vs. multi-dose piperacillin
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Combined groups A and C vs. control group D
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotics)
Number of subjects: 184
Study: 8057223

Group type: EXPERIMENTAL
Intervention: fortified human milk
Number of subjects: 40

Group type: COMPARATOR
Intervention: conventional canned sterilized liquid formula
Number of subjects: 40

Group type: COMPARATOR
Intervention: spray-dried powder formula
Number of subjects: 40

Group type: COMPARATOR
Intervention: ultra-high-temperature (UHT)-treated liquid formula
Number of subjects: 40
Study: 2971692

Group type: EXPERIMENTAL
Intervention: 10 mg acitretin
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 25 mg acitretin
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 50 mg acitretin
Number of subjects: 175

Group type: COMPARATOR
Intervention: 50 mg etretinate
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: All acitretin doses and etretinate
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Acitretin treatment
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Acitretin and etretinate
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 3 weeks after cessation of treatment
Number of subjects: 175
Study: 31854070

Group type: EXPERIMENTAL
Intervention: Burst stimulation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tonic stimulation
Number of subjects: 100
Study: 31855297

Group type: EXPERIMENTAL
Intervention: Cardiometabolic risk score (CRS)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure (DBP)
Number of subjects: 443
Study: 30468526

Group type: EXPERIMENTAL
Intervention: Variable resistance (VR)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Free-weight resistance (FWR)
Number of subjects: 15
Study: 27083774

Group type: EXPERIMENTAL
Intervention: Suicidal Affect‐Behavior‐Cognition Scale and intensive death‐related questions (Experimental condition)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Quality of life scale (Control condition)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Both conditions (Experimental and Control)
Number of subjects: 259
Study: 26477278

Group type: EXPERIMENTAL
Intervention: FBZ >10mg/kg once daily for five consecutive days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: moxidectin (MOX) >0.4 mg/kg once
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 23444134

Group type: EXPERIMENTAL
Intervention: Silicate calcium phosphate (SiCaP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rh-BMP2
Number of subjects: 30
Study: 21568746

Group type: EXPERIMENTAL
Intervention: Tripterygium hypoglaucum Hutch (THH) 3 tablets 3 times daily
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo 3 tablets 3 times daily
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: THH with cetirizine hydrochloride 10 mg once daily
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo with cetirizine hydrochloride 10 mg once daily
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: THH with cetirizine
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo with cetirizine
Number of subjects: 78
Study: 18491970

Group type: EXPERIMENTAL
Intervention: Valganciclovir (900 mg once per day for 8 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (for 8 weeks)
Number of subjects: 26
Study: 16487695

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (P/T) 4 g/500 mg every 6 h
Number of subjects: 437

Group type: COMPARATOR
Intervention: Imipenem/cilastatin (IMP) 500 mg/500 mg every 6 h
Number of subjects: 437
Study: 14665996

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 0
Study: 11832093

Group type: EXPERIMENTAL
Intervention: Intraperitoneal lymphatic chemotherapy with carboplatin (200 mg) and sandostatin (0.1 mg x 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intraperitoneal chemotherapy with carboplatin (200 mg)
Number of subjects: 0
Study: 8869860

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 219

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 219
Study: 1630846

Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene hydrochloride (DP) 150 mg, twice a day, in a double-blind, randomized, placebo-controlled, crossover trial.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene hydrochloride (DP)
Number of subjects: 25
Study: 6328297

Group type: EXPERIMENTAL
Intervention: oral acyclovir
Number of subjects: 35

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 35
Study: 31974590

Group type: EXPERIMENTAL
Intervention: Diaphragm training group (conventional training + diaphragm strengthening)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (conventional training only)
Number of subjects: 52
Study: 30854880

Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide (1.5 µg/min)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PACAP38 levels
Number of subjects: 31

Group type: COMPARATOR
Intervention: Calcitonin gene-related peptide, PACAP38, vasoactive intestinal polypeptide levels during attacks
Number of subjects: 31
Study: 27705076

Group type: EXPERIMENTAL
Intervention: Single-task standing
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Dual-task gait
Number of subjects: 265
Study: 27066860

Group type: EXPERIMENTAL
Intervention: RBP-7000 120mg
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: RBP-7000 90mg
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study: 24497539

Group type: EXPERIMENTAL
Intervention: Tacrolimus/methotrexate/sirolimus (experimental)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Tacrolimus/methotrexate (standard)
Number of subjects: 146
Study: 21985500

Group type: EXPERIMENTAL
Intervention: Oral nifedipine (10 mg tablet, orally, up to five doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous labetalol (escalating doses of 20, 40, 80, 80 and 80 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions (nifedipine and labetalol)
Number of subjects: 0
Study: 20303792

Group type: EXPERIMENTAL
Intervention: Purple grape juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study: 17620675

Group type: EXPERIMENTAL
Intervention: ZoMaxx stent
Number of subjects: 90

Group type: COMPARATOR
Intervention: TriMaxx stent
Number of subjects: 90
Study: 15690201

Group type: EXPERIMENTAL
Intervention: 40-cm² polypropylene mesh (subgroup Ib)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 400-cm² polypropylene mesh (subgroup IIb)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional repair (subgroup Ia)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional repair (subgroup IIa)
Number of subjects: 36
Study: 11755749

Group type: EXPERIMENTAL
Intervention: Enantioselective high-performance liquid chromatographic (HPLC) method for chlorpheniramine and metabolites
Number of subjects: 0